Standard BioTools Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
Standard BioTools Inc. (LAB) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 5.44 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2026-08-05
- Standard BioTools Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-06-30 was 4.40M shares, a 45.28% increase year-over-year.
- Standard BioTools Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-03-31 was 1.04M shares, a 82.40% decline year-over-year.
- Standard BioTools Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-12-31 was 927.00K shares, a 78.16% decline year-over-year.
- Standard BioTools Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-09-30 was 1.50M shares, a 73721.22% increase year-over-year.
- Standard BioTools Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2025 was 11.37M shares, a 167.72% increase from fiscal 2024.
- Standard BioTools Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2024 was 4.25M shares, a 268.34% increase from fiscal 2023.
- Standard BioTools Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2023 was 1.15M shares, a 22.82% decline from fiscal 2022.
- Standard BioTools Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2022 was 1.49M shares, a 1506.45% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 4.40M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | 5.44M shares 10-Q · filed 2026-08-05 | 6.37M shares derived: sum of 3 quarters · filed 2026-08-05 | 7.87M shares derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | 1.04M shares 10-Q · filed 2026-05-06 | 1.97M shares derived: sum of 2 quarters · filed 2026-05-06 | 3.47M shares derived: sum of 3 quarters · filed 2026-05-06 | 6.50M shares derived: sum of 4 quarters · filed 2026-05-06 |
| 2025-12-31 | 927.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | 2.43M shares derived: sum of 2 quarters · filed 2026-03-16 | 5.46M shares derived: sum of 3 quarters · filed 2026-03-16 | 11.37M shares 10-K · filed 2026-03-16 |
| 2025-09-30 | 1.50M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | 4.53M shares derived: sum of 2 quarters · filed 2025-11-04 | 10.44M shares 10-Q · filed 2025-11-04 | 14.69M shares derived: sum of 4 quarters · filed 2025-11-04 |
| 2025-06-30 | 3.03M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-15 | 8.94M shares 10-Q · filed 2025-08-15 | 13.18M shares derived: sum of 3 quarters · filed 2025-08-15 | 13.19M shares derived: sum of 4 quarters · filed 2025-08-15 |
| 2025-03-31 | 5.91M shares 10-Q · filed 2025-05-06 | 10.15M shares derived: sum of 2 quarters · filed 2025-05-06 | 10.16M shares derived: sum of 3 quarters · filed 2025-05-06 | 10.16M shares derived: sum of 4 quarters · filed 2025-05-06 |
| 2024-12-31 | 4.24M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | 4.25M shares derived: sum of 2 quarters · filed 2025-03-11 | 4.25M shares derived: sum of 3 quarters · filed 2025-03-11 | 4.25M shares 10-K · filed 2025-03-11 |
| 2024-09-30 | 2.04K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | 2.79K shares derived: sum of 2 quarters · filed 2024-11-06 | 3.37K shares 10-Q · filed 2024-11-06 | 8.37K shares derived: sum of 4 quarters · filed 2024-11-06 |
| 2024-06-30 | 755.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | 1.34K shares 10-Q · filed 2024-08-06 | 6.34K shares derived: sum of 3 quarters · filed 2024-08-06 | 319.34K shares derived: sum of 4 quarters · filed 2024-08-06 |
| 2024-03-31 | 583.00 shares 10-Q · filed 2024-05-09 | 5.58K shares derived: sum of 2 quarters · filed 2024-05-09 | 318.58K shares derived: sum of 3 quarters · filed 2024-05-09 | 331.58K shares derived: sum of 4 quarters · filed 2024-05-09 |
| 2023-12-31 | 5.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | 318.00K shares derived: sum of 2 quarters · filed 2024-03-01 | 331.00K shares derived: sum of 3 quarters · filed 2024-03-01 | 1.15M shares 10-K · filed 2024-03-01 |
| 2023-09-30 | 313.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | 326.00K shares derived: sum of 2 quarters · filed 2023-11-07 | 1.15M shares 10-Q · filed 2023-11-07 | 1.61M shares derived: sum of 4 quarters · filed 2023-11-07 |
| 2023-06-30 | 13.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | 835.00K shares 10-Q · filed 2023-08-08 | 1.30M shares derived: sum of 3 quarters · filed 2023-08-08 | 1.34M shares derived: sum of 4 quarters · filed 2023-08-08 |
| 2023-03-31 | 822.00K shares 10-Q · filed 2023-05-09 | 1.28M shares derived: sum of 2 quarters · filed 2023-05-09 | 1.32M shares derived: sum of 3 quarters · filed 2023-05-09 | 2.27M shares derived: sum of 4 quarters · filed 2023-05-09 |
| 2022-12-31 | 463.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | 503.00K shares derived: sum of 2 quarters · filed 2023-03-14 | 1.45M shares derived: sum of 3 quarters · filed 2023-03-14 | 1.49M shares 10-K · filed 2023-03-14 |
| 2022-09-30 | 40.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | 984.00K shares derived: sum of 2 quarters · filed 2022-11-09 | 1.03M shares 10-Q · filed 2022-11-09 | 1.04M shares derived: sum of 4 quarters · filed 2023-03-14 |
| 2022-06-30 | 944.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | 991.00K shares 10-Q · filed 2022-08-09 | 1.00M shares derived: sum of 3 quarters · filed 2023-03-14 | 1.03M shares derived: sum of 4 quarters · filed 2023-03-14 |
| 2022-03-31 | 47.00K shares 10-Q · filed 2022-05-09 | 59.00K shares derived: sum of 2 quarters · filed 2023-03-14 | 82.00K shares derived: sum of 3 quarters · filed 2023-03-14 | 117.00K shares derived: sum of 4 quarters · filed 2023-03-14 |
| 2021-12-31 | 12.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | 35.00K shares derived: sum of 2 quarters · filed 2023-03-14 | 70.00K shares derived: sum of 3 quarters · filed 2023-03-14 | 93.00K shares 10-K · filed 2023-03-14 |
| 2021-09-30 | 23.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | 58.00K shares derived: sum of 2 quarters · filed 2021-11-09 | 81.00K shares 10-Q · filed 2021-11-09 | 82.00K shares derived: sum of 4 quarters · filed 2022-03-08 |
| 2021-06-30 | 35.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-06 | 58.00K shares 10-Q · filed 2021-08-06 | 59.00K shares derived: sum of 3 quarters · filed 2022-03-08 | 193.00K shares derived: sum of 4 quarters · filed 2022-03-08 |
| 2021-03-31 | 23.00K shares 10-Q · filed 2021-05-07 | 24.00K shares derived: sum of 2 quarters · filed 2022-03-08 | 158.00K shares derived: sum of 3 quarters · filed 2022-03-08 | 269.00K shares derived: sum of 4 quarters · filed 2022-03-08 |
| 2020-12-31 | 1.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-08 | 135.00K shares derived: sum of 2 quarters · filed 2022-03-08 | 246.00K shares derived: sum of 3 quarters · filed 2022-03-08 | 409.00K shares 10-K · filed 2022-03-08 |
| 2020-09-30 | 134.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | 245.00K shares derived: sum of 2 quarters · filed 2020-11-09 | 408.00K shares 10-Q · filed 2020-11-09 | 455.00K shares derived: sum of 4 quarters · filed 2022-03-08 |
| 2020-06-30 | 111.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | 274.00K shares 10-Q · filed 2020-08-07 | 321.00K shares derived: sum of 3 quarters · filed 2022-03-08 | 347.00K shares derived: sum of 4 quarters · filed 2022-03-08 |
| 2020-03-31 | 163.00K shares 10-Q · filed 2020-05-11 | 210.00K shares derived: sum of 2 quarters · filed 2022-03-08 | 236.00K shares derived: sum of 3 quarters · filed 2022-03-08 | 327.00K shares derived: sum of 4 quarters · filed 2022-03-08 |
| 2019-12-31 | 47.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-08 | 73.00K shares derived: sum of 2 quarters · filed 2022-03-08 | 164.00K shares derived: sum of 3 quarters · filed 2022-03-08 | 211.00K shares 10-K · filed 2022-03-08 |
| 2019-09-30 | 26.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | 117.00K shares derived: sum of 2 quarters · filed 2019-11-08 | 164.00K shares 10-Q · filed 2019-11-08 | |
| 2019-06-30 | 91.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | 138.00K shares 10-Q · filed 2019-08-07 | ||
| 2019-03-31 | 47.00K shares 10-Q · filed 2019-05-07 | |||
| 2018-12-31 | 497.00K shares 10-K · filed 2021-02-25 | |||
| 2017-12-31 | 2.73M shares 10-K · filed 2020-02-27 | |||
| 2016-12-31 | 603.00K shares 10-K · filed 2019-03-18 | |||
| 2015-12-31 | 160.00K shares 10-K · filed 2016-02-29 | |||
| 2014-12-31 | 84.00K shares 10-K · filed 2015-02-26 | |||
| 2013-12-31 | 90.00K shares 10-K · filed 2014-03-12 | |||
| 2012-12-31 | 79.00K shares 10-K · filed 2013-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |